The closing price of Agilon Health Inc (NYSE: AGL) was $1.99 for the day, down -3.40% from the previous closing price of $2.06. In other words, the price has decreased by -$3.40 from its previous closing price. On the day, 2.44 million shares were traded. AGL stock price reached its highest trading level at $2.11 during the session, while it also had its lowest trading level at $1.99.
Ratios:
Our analysis of AGL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.20. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.01.
On April 08, 2025, Bernstein Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $8.50.
Citigroup Upgraded its Sell to Neutral on January 10, 2025, whereas the target price for the stock was revised from $1.75 to $2.25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 13 ’24 when McLoughlin Karen bought 25,000 shares for $2.20 per share. The transaction valued at 55,085 led to the insider holds 73,166 shares of the business.
Battaglia Silvana bought 25,062 shares of AGL for $50,269 on Dec 11 ’24. The Director now owns 66,144 shares after completing the transaction at $2.01 per share. On Nov 25 ’24, another insider, MCKENZIE DIANA, who serves as the Director of the company, bought 12,500 shares for $2.28 each. As a result, the insider paid 28,474 and bolstered with 51,319 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 852740864 and an Enterprise Value of 498699040. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.14 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 0.083 whereas that against EBITDA is -1.812.
Stock Price History:
The Beta on a monthly basis for AGL is 0.15, which has changed by -0.7353723 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, AGL has reached a high of $7.62, while it has fallen to a 52-week low of $1.50. The 50-Day Moving Average of the stock is -11.31%, while the 200-Day Moving Average is calculated to be -32.33%.
Shares Statistics:
AGL traded an average of 3.98M shares per day over the past three months and 2613190 shares per day over the past ten days. A total of 413.02M shares are outstanding, with a floating share count of 303.70M. Insiders hold about 26.63% of the company’s shares, while institutions hold 73.75% stake in the company. Shares short for AGL as of 1752537600 were 17820027 with a Short Ratio of 4.47, compared to 1749772800 on 21228626. Therefore, it implies a Short% of Shares Outstanding of 17820027 and a Short% of Float of 7.04.
Earnings Estimates
The firm’s stock currently is rated by 10.0 analysts. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.04 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.13 and -$0.48 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.22, with 11.0 analysts recommending between -$0.01 and -$0.4.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 18 analysts. It ranges from a high estimate of $1.5B to a low estimate of $1.46B. As of the current estimate, Agilon Health Inc’s year-ago sales were $1.48BFor the next quarter, 18 analysts are estimating revenue of $1.46B. There is a high estimate of $1.51B for the next quarter, whereas the lowest estimate is $1.39B.
A total of 19 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $6.03B, while the lowest revenue estimate was $5.83B, resulting in an average revenue estimate of $5.95B. In the same quarter a year ago, actual revenue was $6.06BBased on 19 analysts’ estimates, the company’s revenue will be $6.58B in the next fiscal year. The high estimate is $7.2B and the low estimate is $6.01B.
